Last reviewed · How we verify

IM risperidone — Competitive Intelligence Brief

IM risperidone (IM risperidone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

phase 3 Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

IM risperidone (IM risperidone) — US Department of Veterans Affairs. IM risperidone is an intramuscular long-acting formulation of the atypical antipsychotic risperidone, which blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IM risperidone TARGET IM risperidone US Department of Veterans Affairs phase 3 Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
Olanzapine-Fluoxetine Combination Olanzapine-Fluoxetine Combination All India Institute of Medical Sciences, Bhubaneswar marketed Atypical antipsychotic + SSRI combination Dopamine D2 receptor, serotonin 5-HT2A receptor, serotonin transporter (SERT)
Quetiapine (drug) Quetiapine (drug) Medical University of Vienna marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
olanzapine + fluoxetine olanzapine + fluoxetine University of Florida marketed Atypical antipsychotic + SSRI combination Dopamine D2 receptor, serotonin 5-HT2A receptor, serotonin transporter (SERT)
Fluoxetine+Olanzapine Fluoxetine+Olanzapine University Health Network, Toronto marketed SSRI + atypical antipsychotic combination Serotonin transporter (SERT), dopamine D2 receptor, serotonin 5-HT2A receptor
Quetiapine Fumarate Sustained Release Quetiapine Fumarate Sustained Release AstraZeneca marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
placebo with Clozapine placebo with Clozapine Shanghai Mental Health Center marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

  1. Shanghai Mental Health Center · 10 drugs in this class
  2. AstraZeneca · 6 drugs in this class
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
  4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
  5. Eli Lilly and Company · 4 drugs in this class
  6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
  7. Medical University of Vienna · 2 drugs in this class
  8. Organon and Co · 2 drugs in this class
  9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  10. H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IM risperidone — Competitive Intelligence Brief. https://druglandscape.com/ci/im-risperidone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: